DMI 9523

Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Antirheumatics; Dipeptides; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Immunomodulators; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase I Crohn's disease
  • Preclinical Chronic obstructive pulmonary disease
  • Research Eye disorders
  • No development reported Inflammation; Neurological disorders; Rhinitis

Most Recent Events

  • 01 Mar 2017 Ampio Pharmaceuticals plans to submit BLA for Osteoarthritis in USA
  • 27 Feb 2017 Ampio Pharmaceuticals receives guidance from the Office of Tissue and Advanced Therapies (OTAT) of the US FDA for the path to approval of Ampion™ in Osteoarthritis
  • 27 Feb 2017 Ampio Pharmaceuticals plans to conduct a pre-approval trial in Osteoarthritis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top